FACULTY SCHOLARSHIP
Publications
Pharmacotherapy Clinical Professor and Director of Quality Assurance Improvement & Accreditation Preparation Terri Levien and J. Roberts and Marcia Fosberg Distinguished Regents Professor of Pharmacotherapy and Director of the Drug Information Center Danial Baker published, “Drug evaluation – bebtelovimab: preliminary evaluation,” in Wolters Kluwer Health’s The Formulary Monograph Service (FMS) in June 2022. Wolters Kluwer Health is a drug and health information publisher, the FMS is a resource used in the formulary decision making process for hospitals and managed care systems on recently released and investigational drugs.
Drug Information Center Resident Regan Smith, Terri Levien and Danial Baker published, “Drug evaluation – pacritinib (Vonjo),” in the FMS in June 2022.
Regan Smith and Danial Baker published, “Drug evaluation – ganaxolone (Ztalmy),” in the FMS in June 2022.
Danial Baker published, “Drug evaluation – mitapivat (Pyrukynd),” in the FMS in June 2022.
Danial Baker published, “Drug evaluation – tebipenem: preliminary evaluation,” in the FMS in June 2022.
Danial Baker published, “Drug utilization evaluation – inclisiran (Leqvio) ,” in the FMS in June 2022.
Terri Levien and Danial Baker published, “Drug evaluation – nirmatrelvir and ritonavir (Paxlovid),” in the FMS in July 2022.
Regan Smith and Danial Baker published, “Drug evaluation – dexmedetomidine sublingual film (Igalmi),” in the FMS in July 2022.
Danial Baker published, “Drug evaluation – faricimab (Vabysmo),” in the FMS in July 2022.
Danial Baker published, “Drug evaluation – lutetium 177LU vipivotide tetraxetan (Pluvicto),” in the FMS in July 2022.
Danial Baker and Terri Levien published, “Drug evaluation – bulevirtide (Hepcludex),” in the FMS in July 2022.
Danial Baker published, “Drug utilization evaluation – dexmedetomidine sublingual film (Igalmi),” in the FMS in July 2022.
Danial Baker published, “Drug evaluation – alpelisib (Vijoice),” in the FMS in August 2022.
Emily Hitt (PharmD ’22), Regan Smith, Terri Levien, and Danial Baker published, “Drug evaluation – Nivolumab and Relatlimab-rmbw (Opdualag),” in the FMS in August 2022.
Terri Levien and Danial Baker published, “Drug evaluation – tapinarof cream (Vtama),” in the FMS in August 2022.
Terri Levien and Danial Baker published, “Drug evaluation – pneumococcal vaccine (Prevnar 20),” in the FMS in August 2022.
Danial Baker, Kaitlyn Walley (PharmD ’22), Terri Levien published, “Drug evaluation – tirzepatide (Mounjaro): updated evaluation,” in the FMS in August 2022.
Danial Baker published, “Drug utilization evaluation – tirzepatide (Mounjaro) ,” in the FMS in August 2022.
Danial Baker published, “Drug evaluation – trientine tetrahydrochloride (Cuvrior),” in the FMS in September 2022.
Ashley Rittenhouse (PharmD ’23), Terri Levien, and Danial Baker published, “Drug evaluation – oteseconazole (Vivjoa),” in the FMS in September 2022.
Tristan Hilton (PharmD ’23), Terri Levien, and Danial Baker published, “Drug evaluation – Mavacamten (Camzyos),” in the FMS in September 2022.
Danial Baker published, “Drug evaluation – daprodustat: preliminary evaluation,” in the FMS in September 2022.
Regan Smith, Terri Levien, Danial Baker published, “Drug evaluation – vonoprazan, amoxicillin (Voquezna Dual Pak) and vonoprazan, amoxicillin, clarithromycin (Voquezna Triple Pak),” in the FMS in September 2022.
Danial Baker published, “Drug utilization evaluation – vonoprazan, amoxicillin (Voquezna Dual Pak) and vonoprazan, amoxicillin, clarithromycin (Voquezna Triple Pak),” in the FMS in September 2022.
Pharmacotherapy Vice Chair & Allen I. White Distinguished Professor Joshua J. Neumiller, and two co-authors published, “GLP-1 receptor agonists in the treatment of patients with type 2 diabetes and chronic kidney disease,” in Kidney and Dialysis in May 2022.
Pharmaceutical Sciences Assistant Professor Ayesha Ahmed and two co-authors published, “Explosions, burn injuries and adverse health effects of electronic nicotine delivery systems: a review of current regulations and future perspectives,” in Journal of Pharmacy and Pharmaceutical Sciences, a peer-reviewed scientific journal, in September 2021.
Ayesha Ahmed and several co-authors published, “Advances in molecular pathogenesis of hidradenitis suppurativa: dysregulated keratins and ECM signaling,” in Seminars in Cell and Developmental Biology, a peer-reviewed scientific journal, in August 2022.
Ayesha Ahmed and three co-authors published, “Is glyceryl trinitrate, a nitric oxide donor responsible for ameliorating the chemical-induced tissue injury in vivo?,” in Molecules, a peer-reviewed scientific journal, in July 2022.
Ayesha Ahmed and one co-author published, “The complexity in the diagnosis and treatment of symptoms in electronic cigarette users during the COVID-19 pandemic,” in Pharmacoepidemiology, a peer-reviewed scientific journal, in July 2022.
Allison Rembert (PharmD ’24), Adrian Baker (PharmD ’24), and Joshua J. Neumiller, published “The non-steroidal mineralocorticoid receptor antagonist finerenone: a new option for patients with diabetic kidney disease,” in Diabetes in Control in June 2022.
Presentations
Research Associate Sandhya Subash (Prasad lab) presented the poster, “Proteomics-informed improved IVIVE of aldehyde oxidase mediated drug metabolism: The use of relative expression (REF) and inter-system extrapolation factor (ISEF),” at the Gordon Research Conference (GRC) in July 2022.
Service
Joshua J. Neumiller was featured on the episode, “Future type 2 diabetes drugs: exciting and a little scary,” of the Medscape InDiscussion Type 2 Diabetes Podcast on July 12, 2022.
Joshua J. Neumiller and two others held a panel discussion titled, “Clinical update: treatment intensification with non-insulin therapies,” as part of the Hands On: Tips to Improve Diabetes Care Webinar Series by the American Diabetes Association on August 9, 2022.
STUDENT ACHIEVEMENT
Pharmaceutical Sciences and Molecular Medicine students
Deepak Ahire (Prasad lab) presented the poster and oral presentation, “Role of UGT2B17 in the metabolism of prescription drugs and steroids is underappreciated,” at the inaugural Gordon Research Seminar (GRS) in July 2022.
Doctor of Pharmacy students
Allison Rembert (’24) and Adrian Baker (’24) with faculty co-author Joshua J. Neumiller, published “The non-steroidal mineralocorticoid receptor antagonist finerenone: a new option for patients with diabetic kidney disease,” in Diabetes in Control in June 2022.
Ashley Rittenhouse (’23) with faculty co-authors Terri Levien and Danial Baker published, “Drug evaluation – oteseconazole (Vivjoa),” in the FMS in September 2022.
Tristan Hilton (’23) with faculty co-authors Terri Levien and Danial Baker published, “Drug evaluation – Mavacamten (Camzyos),” in the FMS in September 2022.
Kaitlyn Walley (’22) with faculty co-authors Terri Levien and Danial Baker published, “Drug evaluation – tirzepatide (Mounjaro): updated evaluation,” in the FMS in August 2022.
Emily Hitt (PharmD ’22) with faculty co-authors Regan Smith, Terri Levien, and Danial Baker published, “Drug evaluation – Nivolumab and Relatlimab-rmbw (Opdualag),” in the FMS in August 2022.
Washington State University was selected as one of the top ten teams in the Good Neighbor Pharmacy National Community Pharmacists Association (NCPA) Pruitt-Schutte Student Business Plan Competition. Student pharmacists Kennedy Erickson, Jeannie Ko, Michael Asfha, and Kayla Huber made up the team with faculty advisors Julie Akers, Nicole Rodin, and Damianne Brand.